▶ Полный текст поста
TL;DR DRTS is a company with true (proven!) life saving potential, and as can be seen by the recent increase in volume and SP, the results are starting to get recognition, and this week they are expected to announce the most exciting data yet.
DRTS has discovered how to deliver alpha radiation into the tumor, cleaning out the cancer while sparing healthy tissue.
This is exciting in many ways, for example the high effectiveness, the lack of side effects, the fact that it’s a single session outpatient procedure and more.
But maybe most exciting, is the fact that it’s the same treatment for all solid tumors, and has yet to find a tumor type that doesn’t respond.
That enables the company to go after the most high unmet needs cancers, and the results are unbelievable. For example last week they announced Complete Response in Recurring GBM, before that they announced 100% Disease Control Rate in Pancreatic Cancer, and for Skin Cancer (already approved in Japan) they completed “phase 3” with prior trials showing 100% complete response and testimonials to show for.
The company has everything set up perfectly, from the experienced team to the funding, already built and approved commercial manufacturing, 50+ clinical sites worldwide, many different FDA trials in different indications, it’s truly only down to execution (which they are acing) and continuous good results.
Speaking of continuous good results, this weeks news, news that should have everyone at the edge of their seats, is that DRTS is expected to share Pancreatic Cancer Survival Data at the upcoming ASCO annual meeting.
To date all DRTS results have exceeded expectations, and last month when RVMD announced PanC survival data they added 10 billion to their market cap, while DRTS (different treatment) could demonstrate even better numbers than that while trading at about a 1 billion market cap.
NFA and DYOR, the regular biotech risks apply, but this is an opportunity to join the journey of a company that could change cancer treatment forever, can become an industry leading platform, and the expected news could be a big step forward towards saving millions and making millions.